KALA BIO, Inc.
KALA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479419
No open-market purchases or sales by KALA BIO, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.21M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −15 vs. previous quarter
- 15
- 13F valueReported value at the end of Q2 2026
- $1.21M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding KALA, Q2 2026
No superinvestor reported holding KALA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by KALA BIO, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 24, 2025 (view filing) | Oct 22 | 2 days | Kharabi DariusCHIEF BUSINESS OFFICER | SSale | −20.8K | $0.83 | −$17.3K | −33.3%41.8K after | |
| Oct 24, 2025 (view filing) | Oct 22-23 | 2 days | Reumuth MaryCHIEF FINANCIAL OFFICER | SSale | −33.2K | $0.8297 | −$27.5K | −53.5%28.9K after | 2 lots |
| Oct 24, 2025 (view filing) | Oct 22 | 2 days | Bazemore ToddDirector | SSale | −47.8K | $0.83 | −$39.6K | −57.1%35.9K after | |
| Oct 24, 2025 (view filing) | Oct 23 | 1 day | Iwicki Mark TDirector | SSale | −154.9K | $0.81 | −$125.5K | −59.9%103.5K after | |
| Oct 24, 2025 (view filing) | Oct 22 | 2 days | Brazzell Romulus KSEE REMARKS | SSale | −46.7K | $0.83 | −$38.8K | −56.5%36.0K after | |
| Oct 2, 2025 (view filing)4:47 PM ET | Sep 30-Oct 1 | 2 days | Baker Julian and 3 othersOther: Former 10% owner | SSale | −730.4K | $1.45 | −$1.06M | −63.2%425.0K after | 4 lots |
| Jun 26, 2025 (view filing) | Jun 24 | 2 days | Kharabi DariusCHIEF BUSINESS OFFICER | SSale | −4.51K | $4.01 | −$18.1K | −6.7%62.6K after | |
| Jun 26, 2025 (view filing) | Jun 24 | 2 days | Reumuth MaryCHIEF FINANCIAL OFFICER | SSale | −3.63K | $4.01 | −$14.6K | −5.5%62.1K after | |
| Jun 26, 2025 (view filing) | Jun 24 | 2 days | Bazemore ToddSEE REMARKS | SSale | −4.06K | $4.01 | −$16.3K | −4.6%83.7K after | |
| Jun 26, 2025 (view filing) | Jun 24 | 2 days | Brazzell Romulus KSEE REMARKS | SSale | −5.25K | $4.01 | −$21.1K | −6.0%82.7K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in KALA BIO, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 220,623 | $381.7K | 0.00% | +160,074+264.4% | Added |
| Geode Capital Management, LLC | 145,152 | $251.1K | 0.00% | −115,909−44.4% | Reduced |
| Vanguard Fiduciary Trust Co | 101,396 | $175.4K | 0.00% | +71,768+242.2% | Added |
| State Street Corp | 88,570 | $153.2K | 0.00% | +59,994+209.9% | Added |
| BlackRock, Inc. | 71,542 | $123.8K | 0.00% | +60,733+561.9% | Added |
| Northern Trust Corp | 41,606 | $72.0K | 0.00% | +30,082+261.0% | Added |
| Qube Research & Technologies Ltd | 11,073 | $19.2K | 0.00% | +11,073 | New |
| Goldman Sachs Group Inc | 10,921 | $18.9K | 0.00% | −3,127−22.3% | Reduced |
| UBS Group AG | 9,057 | $15.7K | 0.00% | −57,814−86.5% | Reduced |
| Tower Research Capital LLC (TRC) | 616 | $1.07K | 0.00% | +616 | New |